SCOPE Rounds: Gastroenterology 2025 | Autoimmune Liver Disease Through the Ages

By the end of this program, the learner will be able to:

• Discuss the optimum induction and maintenance regimens in first-, second-, and third-line therapy for autoimmune liver disease (AILD), including challenges associated with new drug development

• Apply risk stratification strategies to patient populations, at presentation and over time

• Describe the changing epidemiology of AILD and how this may impact liver and gastroenterology services moving forward

• Explain how variations in clinical practice influence long-term clinical outcomes for patients

Registration open to Healthcare Professionals only.

Register now